Karyopharm Therapeutics Inc. (NASDAQ:KPTI) insider Ran Frenkel sold 3,309 shares of Karyopharm Therapeutics stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $10.06, for a total value of $33,288.54. Following the sale, the insider now directly owns 14,691 shares of the company’s stock, valued at approximately $147,791.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) opened at 9.29 on Thursday. The company’s 50 day moving average price is $8.74 and its 200 day moving average price is $8.27. Karyopharm Therapeutics Inc. has a 12 month low of $4.83 and a 12 month high of $19.41. The stock’s market capitalization is $383.15 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Monday, November 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.12. Equities analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.00) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

A number of research firms recently commented on KPTI. Zacks Investment Research raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Friday, November 11th. Canaccord Genuity reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, November 8th. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, November 8th. Wedbush reiterated an “outperform” rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, November 8th. Finally, Jefferies Group reiterated a “buy” rating and set a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, November 8th. One equities research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Karyopharm Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $15.47.

A number of hedge funds have recently bought and sold shares of the company. BlackRock Advisors LLC boosted its stake in Karyopharm Therapeutics by 15.1% in the third quarter. BlackRock Advisors LLC now owns 11,410 shares of the company’s stock worth $111,000 after buying an additional 1,498 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new stake in Karyopharm Therapeutics during the second quarter valued at approximately $136,000. Emerald Acquisition Ltd. boosted its stake in Karyopharm Therapeutics by 46.2% in the third quarter. Emerald Acquisition Ltd. now owns 14,327 shares of the company’s stock valued at $139,000 after buying an additional 4,527 shares in the last quarter. Nationwide Fund Advisors boosted its stake in Karyopharm Therapeutics by 38.3% in the second quarter. Nationwide Fund Advisors now owns 21,258 shares of the company’s stock valued at $143,000 after buying an additional 5,886 shares in the last quarter. Finally, Endurance Wealth Management Inc. boosted its stake in Karyopharm Therapeutics by 166.7% in the third quarter. Endurance Wealth Management Inc. now owns 16,000 shares of the company’s stock valued at $156,000 after buying an additional 10,000 shares in the last quarter. 55.99% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.